On August 26, 2024, Stephen Betz, Chief Scientific Officer of Crinetics Pharmaceuticals Inc (NASDAQ:CRNX), sold 3,000 shares of the company at a price of $53.19 per share. The transaction was documented in a recent SEC filing. Following this sale, the insider now owns 69,611 shares of Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
Over the past year, Stephen Betz has sold a total of 39,000 shares of Crinetics Pharmaceuticals Inc. and made no purchases of shares. The company’s insider transaction history shows a pattern of 36 insider sales and no insider purchases over the past year.
Crinetics Pharmaceuticals Inc. shares were trading at $53.19 on the day of the transaction, giving the company a market capitalization of around $4.35 billion. This valuation reflects the stock’s current GF value, price-to-earnings ratio, price-to-sales ratio, price-to-book ratio and price-to-free cash flow ratio.
This insider sale may be of interest to investors who track insider behavior as an indicator of company performance and valuation trends.
This article created by GuruFocus is intended to provide general insights and does not constitute tailored financial advice. Our commentary is based on historical data and analyst forecasts, uses an unbiased methodology and is not intended to serve as specific investment advice. It does not contain a recommendation to buy or sell any stock and does not take into account any individual investment objectives or financial circumstances. Our goal is to provide long-term, fundamental, data-driven analysis. Note that our analysis may not include the most recent, price-sensitive company announcements or qualitative information. GuruFocus does not hold a position in any stocks mentioned here.
This article first appeared on GuruFocus.
